{
    "cancer_info": {
        "cancer_name": "Thymic Epithelial Tumors (Thymomas and Thymic Carcinomas)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Chest CT with contrast",
            "Chest MRI (if CT inconclusive/contraindicated)",
            "FDG PET/CT (skull base to mid-thigh)",
            "Serum beta-hCG test",
            "Serum AFP test",
            "CBC",
            "Platelet count",
            "LDH test",
            "Anti-AChR antibodies test (for myasthenia gravis screening)",
            "Paraneoplastic autoantibodies test (if symptomatic)",
            "Core needle biopsy (preferred)",
            "Open biopsy (if core biopsy non-diagnostic)",
            "Fine needle aspiration (FNA) biopsy",
            "Histologic Classification (WHO subtypes)",
            "Pulmonary function tests (if clinically indicated)",
            "Lymph Node Dissection (per ITMIG map)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage I (Encapsulated, no microscopic invasion)",
            "risk_group": "Thymoma",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Resectable",
                    "plan_name": "Total thymectomy",
                    "plan_details": "Complete (R0) resection via VATS or open sternotomy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant treatment",
                    "patient_subgroup": "After R0 resection",
                    "plan_name": "Surveillance",
                    "plan_details": "Chest CT every 6-12 months for 2 years, then annually until 10 years",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage II (Microscopic/macroscopic invasion)",
            "risk_group": "Thymoma",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Resectable",
                    "plan_name": "Total thymectomy",
                    "plan_details": "Complete resection with extended techniques if needed",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant treatment",
                    "patient_subgroup": "After resection",
                    "plan_name": "Postoperative radiotherapy",
                    "plan_details": "45-54 Gy for R0/R1 resection",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Stage III/IVA (Invasion of adjacent organs/pleural dissemination)",
            "risk_group": "Thymoma",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Resectable",
                    "plan_name": "Extended resection",
                    "plan_details": "Total thymectomy with involved organ resection (lung/pericardium)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Neoadjuvant treatment",
                    "patient_subgroup": "Borderline resectable",
                    "plan_name": "Cisplatin-based chemotherapy",
                    "plan_details": "CAP regimen: Cisplatin + Doxorubicin + Cyclophosphamide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant treatment",
                    "patient_subgroup": "After resection",
                    "plan_name": "Postoperative radiotherapy",
                    "plan_details": "60-70 Gy for R2 resection; 45-54 Gy for R0/R1",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Stage IVB (Distant metastases)",
            "risk_group": "Thymoma",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Advanced disease",
                    "plan_name": "CAP regimen",
                    "plan_details": "Cisplatin 50mg/m2 + Doxorubicin 50mg/m2 + Cyclophosphamide 500mg/m2",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "Refractory disease",
                    "plan_name": "Everolimus",
                    "plan_details": "mTOR inhibitor (10mg daily)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "Refractory disease",
                    "plan_name": "Gemcitabine/Capecitabine",
                    "plan_details": "Gemcitabine 1000mg/m2 + Capecitabine 1000mg/m2",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Any stage",
            "risk_group": "Thymic Carcinoma",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Resectable",
                    "plan_name": "Total thymectomy",
                    "plan_details": "Complete resection with extended techniques if needed",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant treatment",
                    "patient_subgroup": "Post-resection",
                    "plan_name": "Radiotherapy ± chemotherapy",
                    "plan_details": "45-60 Gy RT with CAP or carboplatin/paclitaxel",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Advanced/metastatic",
                    "plan_name": "Carboplatin/Paclitaxel ± Ramucirumab",
                    "plan_details": "Carboplatin AUC5-6 + Paclitaxel 200mg/m2 ± Ramucirumab 10mg/kg",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "PD-L1 positive",
                    "plan_name": "Pembrolizumab",
                    "plan_details": "200mg every 3 weeks (high toxicity risk)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "Refractory disease",
                    "plan_name": "Lenvatinib",
                    "plan_details": "Multikinase inhibitor (24mg daily)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Unresectable disease",
            "risk_group": "All histologies",
            "treatment_plans": [
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "Locally advanced",
                    "plan_name": "Radiation therapy",
                    "plan_details": "60-70 Gy using IMRT/VMAT/proton therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Systemic therapy",
                    "patient_subgroup": "With great vessel involvement",
                    "plan_name": "Neoadjuvant chemotherapy",
                    "plan_details": "CAP or carboplatin/paclitaxel regimens",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "Octreotide/Dotatate PET-CT: Guides octreotide therapy in neuroendocrine-differentiated tumors",
            "c-KIT Mutations: Predicts response to sunitinib in thymic carcinomas (10% prevalence)",
            "PD-L1 Expression: Predicts pembrolizumab response in thymic carcinoma (high toxicity risk)",
            "Anti-AChR Antibodies: Diagnostic for myasthenia gravis in thymoma patients (30-45% prevalence)",
            "WHO Histologic Classification: Determines prognosis and treatment strategy (B3 thymoma correlates with worse outcomes)"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：胸腺瘤和胸腺癌.txt"
}